Supreme Court
Myriad Decision: Six Points Every Biotech CEO Must Consider
Regardless of whether you agree or disagree on the fundamentals of the Supreme Court’s ruling in Association for Molecular Pathology v. Myriad Genetics, the decision raises six important issues biotech executives will need to address ...Read more
Supreme Court
Brand/Generic Patent Settlements Become More Risky
Pharma can anticipate more costly, drawn-out patent litigation as a result of the Supreme Court’s ruling in FTC v. Actavis, which found that “pay-for-delay” could violate antitrust laws, writes Jill Wechsler ...Read More
Technology
2013: The Year of Mobile Health
Mobile health is getting some serious attention this month — from an unusual but inspiring new Apple ad to some grandiose forecasts for mHealth’s potential impact on European budgets, the first reimbursable mobile app, and an ambitious new study setting out to spotlight the best examples of mHealth by the leading pharma companies ...Read more
Video
CEO Flemming Ornskov on Shire Strategy
Shire’s new CEO Ornskov stopped by the Pharm Exec office to discuss the
importance of alignment with the customer and the untapped potential from
Shire’s expertise in that sweet spot in specialty — rare diseases ...Read more
Marketing
Wanted: A Trusted Advisor
Al Topin looks at redefining your ad agency’s role in today’s complex pharma market ...Read more
Global
Helping Patients Lead the Way in the New NHS
Jacky Law investigates how pharma companies can effectively become part of NHS England ...Read more
Global
China Report
China is the third largest pharmaceutical market in the world and will become the second largest ahead of Japan by 2015. Everything you need to know to do business in the country; key economic sector data and exclusive interviews from regional leaders ...Read more
|
